{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih77lrjfmz4kjbwikvms6bpt5pfpqfthq7g4q2qon3lo5loussste",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mkirayu2lji2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaxgqjgyepr5xrxbewb5yp6tniwwi2ydf2f2n423fev5culixmbmi"
    },
    "mimeType": "image/jpeg",
    "size": 60473
  },
  "path": "/2026/04/27/intellia-therapeutics-phase-3-trial-hereditary-angioedema-crispr-treatment/?utm_campaign=rss",
  "publishedAt": "2026-04-27T11:01:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "CRISPR",
    "drug development",
    "FDA",
    "gene editing",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?",
  "title": "STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial",
  "updatedAt": "2026-04-27T10:33:38.000Z"
}